Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01499147 · ClinicalTrials.gov registry record · NA
Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies
A NA study, sponsored by University of Illinois at Chicago.
- Completed
- Registry status
- NA
- Development phase
- 100
- Enrollment target
NCT01499147 is a NA study that has completed, run by University of Illinois at Chicago. The registered enrollment target is 100 participants.
The verdict
NCT01499147, a NA study, has completed, sponsored by University of Illinois at Chicago.
- COMPLETED
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
Study Summary
New conditioning regimens are still needed to maximize efficacy and limit treatment-related deaths of allogeneic transplantation for advanced hematologic malignancies. Over the past several years, the investigators have evaluated several new conditioning regimens that incorporate fludarabine, a novel immunosuppressant that has limited toxicity and that has synergistic activity with alkylating agents. Recent data have suggested that fludarabine may be used in combination with standard doses of oral or IV busulfan, thus reducing the toxicity previously observed with cyclophosphamide/ busulfan regimens.
Interventions
- DRUG ATG
- DRUG fludarabine/busulfan
- DRUG fludarabine/ melphalan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2000-02 |
| Est. Completion | 2013-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01499147
The ClinicalTrials.gov registry entry for NCT01499147 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Illinois at Chicago, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which ATG is the first listed.
NCT01499147 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01499147 about?
NCT01499147 is a clinical study titled "Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies". New conditioning regimens are still needed to maximize efficacy and limit treatment-related deaths of allogeneic transplantation for advanced hematologic malignancies. Over the past several years, the investigators have evaluated several new conditioning regimens that incorporate fludarabine, a nove...
What is the current status of trial NCT01499147?
This trial is currently completed. It is a NA study. The enrollment target is 100 participants. The study started on 2000-02. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01499147?
The interventions under investigation include: ATG (DRUG), fludarabine/busulfan (DRUG), fludarabine/ melphalan (DRUG).
Who is sponsoring clinical trial NCT01499147?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.